Olema Pharmaceuticals (NASDAQ:OLMA) Insider Shane William Charles Kovacs Sells 100,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $28.73, for a total transaction of $2,873,000.00. Following the completion of the transaction, the insider directly owned 139,727 shares in the company, valued at $4,014,356.71. This trade represents a 41.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shane William Charles Kovacs also recently made the following trade(s):

• On Tuesday, January 13th, Shane William Charles Kovacs sold 3,822 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.01, for a total value of $107,054.22.

Olema Pharmaceuticals Trading Up 1.5%

Shares of OLMA opened at $29.19 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. Olema Pharmaceuticals, Inc. has a 52-week low of $2.86 and a 52-week high of $36.26. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -15.61 and a beta of 1.92. The business’s fifty day moving average is $24.70 and its 200-day moving average is $13.11.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Equities analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

More Olema Pharmaceuticals News

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Broker upgrades and higher price targets from multiple firms (Citigroup, Oppenheimer, Piper Sandler, Goldman Sachs) lifted analyst support and raised consensus upside (average target ≈ $41), which likely boosted investor confidence. MarketBeat Analyst Coverage
• Positive Sentiment: Olema published an investor presentation emphasizing its palazestrant (OP‑1250) development strategy and combination plans with CDK4/6 inhibitors — useful context for upcoming data and commercial potential that can support the stock. Investor Presentation
• Neutral Sentiment: Institutional ownership is very high (~91.8%), and a mix of recent modest institutional buys/sells was reported — this large institutional base can amplify moves but is not an immediate directional catalyst. Institutional Holdings
• Negative Sentiment: Significant insider selling was disclosed this week: Shane Kovacs sold 100,000 shares (~$2.87M at $28.73) and additional smaller lots; Director/insider David Myles sold multiple blocks (including 50,000 at ~$27.60 and 10,000 at ~$28.34). Large insider sales (noted ownership percentage drops) can weigh on sentiment even if management retains meaningful stakes. Kovacs SEC Filing Myles SEC Filing

Analyst Ratings Changes

A number of equities analysts recently issued reports on OLMA shares. Guggenheim started coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, October 8th. They set a “buy” rating and a $20.00 price objective for the company. Citigroup upped their price target on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, December 12th. The Goldman Sachs Group increased their price target on Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. HC Wainwright boosted their price objective on Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, JPMorgan Chase & Co. upped their target price on Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.00.

Institutional Trading of Olema Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its position in Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after purchasing an additional 477 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Olema Pharmaceuticals in the 3rd quarter valued at about $53,000. Ameritas Investment Partners Inc. increased its stake in shares of Olema Pharmaceuticals by 55.4% in the second quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after buying an additional 2,168 shares during the period. Farther Finance Advisors LLC raised its position in shares of Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock worth $29,000 after acquiring an additional 5,866 shares during the last quarter. Finally, FNY Investment Advisers LLC lifted its stake in shares of Olema Pharmaceuticals by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 5,000 shares during the period. Institutional investors own 91.78% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.